Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Rivaroxaban Film-coated Tablets under Fasting Condition
TCTR20250710006Phase 1Completed
- Sponsor
- Mankind Pharma
- Start
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of rivaroxaban in venous thromboembolism (VTE), nonvalvular atrial fibrillation (NVAF) and pulmonary embolism (PE) (2 arms), sponsored by Mankind Pharma. Started Aug 2025; status: completed.
02
Drugs
rivaroxaban
03
Conditions
venous thromboembolism (VTE)nonvalvular atrial fibrillation (NVAF)pulmonary embolism (PE)
Beyond the preview
Go deeper on TCTR20250710006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20250710006.